Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
See All Experts
story of the week
Published in Diabetes and
1 other channel

Journal Scan / Research · February 04, 2016

Heart Failure Outcomes With Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk

European Heart Journal

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Benjamin Scirica MD

European Heart Journal
Heart Failure Outcomes With Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: Results of the EMPA-REG OUTCOME® Trial
Eur Heart J 2016 Jan 26;[EPub Ahead of Print], D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, OE Johansen, HJ Woerle, UC Broedl, SE Inzucchi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated